Focused on helping health sciences organizations increase the productivity and effectiveness of their product development programs, Oracle Health Sciences introduced the newest version of Oracle Health Sciences Clinical Development Analytics. Driven by input from industry partners, the comprehensive business intelligence application includes new functionality that expands visibility into clinical programs and studies, improves the quality and timeliness of clinical trial data and helps to simplify and prioritize the rapidly expanding responsibilities of study managers, clinical data managers, and site monitors.
“Clinical trial sponsors and their CRO partners, navigating increasingly complex and lengthy development cycles, are intently focused on improving data quality and clinical program productivity while reducing costs,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. “The newest version of Oracle Health Sciences Clinical Development Analytics, which features integrated content, expanded dashboards, and optimized reporting, delivers the insight that study sponsors, managers, and monitors require to achieve these goals and accelerate the delivery of new products to the market.”
The enhanced solution helps to increase resource utilization by delivering advanced dashboards specifically tailored to clinical trial roles. It features expanded drill-down functionality and key performance indicators that identify areas requiring action or attention, such as targeting underperforming sites. The solution enables organizations to merge data from multiple clinical trial sources, providing a unified view across operational systems on a single screen.
New de-duplication technology supports reports that combine both clinical operations and data management information to monitor enrollment progress, optimize productivity at site visits and help to reduce monitoring-related travel expenses. Oracle Health Sciences Clinical Development Analytics also delivers visibility across the entire portfolio of clinical trials, which enables greater insight into subject recruitment and site performance to empower managers and clinical monitors to better target resources to key sites which will help accelerate trial completion.
With more than 100 pre-built reports and over 500 pre-built measurements and attributes for custom reporting, Oracle Health Sciences Clinical Development Analytics can provide immediate business benefit out of the box, while providing an extensible framework for adding additional metrics aligned to targeted business processes. To enable anytime, anywhere access, the solution can be used in conjunction with Oracle Business Intelligence Mobile application for Apple iPhone and iPad to give mobile users access to the latest performance management information.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.